Life Technologies Corp. (LIFE: Quote) said it will exhibit products across the spectrum of basic, translational and clinical cancer research during the American Association of Cancer Research or AACR Annual Meeting 2012, taking place March 31 - April 4, in Chicago, Illinois.
Presentations included in this exhibition are triple negative breast cancer, Semiconductor sequencing of melanoma samples, the company said.
Triple negative breast tumors, which make up nearly 20 percent of breast cancers, do not respond to treatment with targeted therapies such as Herceptin. To investigate new options for these patients, the first clinical trial of whole-genome sequencing for women with triple negative breast cancer was initiated in March 2010; early results will be presented by John Carpten, head of the Integrated Cancer Genomics Division at the Phoenix-based Translational Genomics Research Institute or Tgen.
In addition, George Watts, research assistant professor and co-director of the Genomics Shared Service at The University of Arizona Cancer Center, will present a poster demonstrating accurate, cost-effective sequencing of six commonly mutated genes in archived research samples from metastatic melanoma patients using the Life Technologies Ion Personal Genome Machine system.
| || |
| To receive FREE breaking news email alerts for Life Technologies Corporation and others in your portfolio|
by RTT Staff Writer
For comments and feedback: email@example.com